CD274 and cancer: Second, even if the population is homogeneous for the type, stage of cancer (all patients with stage IV NSCLC), and PS, the data are not homogeneous for the type of treatment and line of therapy, including patients who have used both PD-1/PD-L1 inhibitors as first-, second-, and third-line therapy.